Current Allergy and Asthma Reports

, 14:418

Genotyping for Severe Drug Hypersensitivity

Authors

  • Eric Karlin
    • Vanderbilt University School of Medicine
    • Vanderbilt University School of Medicine
    • Institute for Immunology and Infectious DiseasesMurdoch University
ANAPHYLAXIS AND DRUG ALLERGY (DA KHAN AND M CASTELLS, SECTION EDITORS)

DOI: 10.1007/s11882-013-0418-0

Cite this article as:
Karlin, E. & Phillips, E. Curr Allergy Asthma Rep (2014) 14: 418. doi:10.1007/s11882-013-0418-0
Part of the following topical collections:
  1. Topical Collection on Anaphylaxis and Drug Allergy

Abstract

Over the past decade, there have been significant advances in our understanding of the immunopathogenesis and pharmacogenomics of severe immunologically-mediated adverse drug reactions. Such T-cell-mediated adverse drug reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug-induced liver disease (DILI) and other drug hypersensitivity syndromes have more recently been shown to be mediated through interactions with various class I and II HLA alleles. Key examples have included the associations of HLA-B*15:02 and carbamazepine induced SJS/TEN in Southeast Asian populations and HLA-B*57:01 and abacavir hypersensitivity. HLA-B*57:01 screening to prevent abacavir hypersensitivity exemplifies a successful translational roadmap from pharmacogenomic discovery through to widespread clinical implementation. Ultimately, our increased understanding of the interaction between drugs and the MHC could be used to inform drug design and drive pre-clinical toxicity programs to improve drug safety.

Keywords

GenotypingAltered peptide repertoireDILIDRESSHuman leukocyte antigenDrug hypersensitivityMajor histocompatibility complexPharmacogeneticsPharmacogenomicsStevens-Johnson syndromeToxic epidermal necrolysisTranslationSCAR

Copyright information

© Springer Science+Business Media New York 2014